Leukemia remission rates: What remission means and what to expect

Table of contents 

• Introduction
• What does remission mean for leukemia patients?
• Leukemia remission rates by type
• What factors affect leukemia remission rates?
• How is remission measured?
• Can leukemia come back after remission?
• Life after leukemia remission
• Advances improving leukemia remission rates
• FAQs
• How Blood Cancer United supports people living with leukemia
• References

Key takeaways 

• Remission in leukemia means signs and symptoms have improved or disappeared, and no leukemia cells are detected with standard tests. Blood counts return to normal. 
• Rates depend on leukemia type, age, health, and treatment. 
• Factors affecting remission include age, leukemia subtype, genetic mutations, overall health, treatment response, MRD status, and eligibility for stem cell transplant. 
• Doctors use blood tests, bone marrow biopsies, MRD testing, and imaging to assess remission status. 
• Leukemia can return after remission, especially if a person is MRD-positive, with high-risk genetics, older age, or incomplete first response. Regular monitoring is crucial. 
• Ongoing follow-ups, blood count monitoring, emotional support, and survivorship resources are important for long-term health and well-being. 
• Targeted therapies, immunotherapy, precision medicine, improved MRD testing, and advances in stem cell transplantation have all contributed to higher remission rates and better outcomes. 

When someone is diagnosed with leukemia, the hope is that they will achieve remission. Remission means the disease is no longer detectable on standard tests and symptoms ease or disappear. Remission essentially means that the leukemia is dormant, though ongoing monitoring is still needed.

Understanding what remission means, how doctors measure it, and what affects leukemia remission rates can help you and your family know what to expect if you or someone you love is diagnosed.

What does remission mean for leukemia patients? 

In remission, your signs and symptoms improve or disappear. Your doctor can no longer find leukemia cells with standard tests, or the number of leukemia cells in your blood or bone marrow is significantly reduced. Your blood counts may also return to normal (Litzow, 2025). Remission may be classified as either partial or complete depending on whether leukemia cells are still detectable. 

An important distinction is that remission does not necessarily mean you are cured. While both are good things, remission means your symptoms have improved or are gone and tests find no cancer cells, but a small number may remain and could cause the disease to return. A cure is when all the leukemia cells are gone, and the risk of relapse is extremely low—though your care team will explain what that means for your specific situation. 

Complete remission 

With complete remission, standard tests find no leukemia cells in your blood or bone marrow, your blood counts are normal, and symptoms such as swollen lymph nodes or an enlarged spleen usually improve or disappear. Because a small number of leukemia cells can remain below the level standard tests can detect, you’ll still need regular checkups. Sometimes, additional treatment is needed to help keep the disease from returning. 

Partial remission 

In partial remission, treatment has reduced the leukemia cells, but some remain in your blood or bone marrow. Your symptoms may improve even if your blood counts aren’t fully normal yet. It’s a sign treatment is helping, though you’ll likely need more therapy to control the disease and lower the risk of relapse. 

MRD-negative remission 

MRD stands for “measurable residual disease,” the very small number of cancer cells that regular tests might miss. With MRD-negative remission, even special tests can’t find any leftover leukemia cells. Reaching it reflects a deeper response to treatment and lowers your risk of relapse, which makes it an important goal in leukemia care.

Leukemia remission rates by type 

Leukemia remission rates vary by the type of leukemia. 

Acute myeloid leukemia (AML)

Remission rates for AML depend on age and overall health. Most younger adults reach complete remission after initial treatment, with rates around 60–85%. Older adults usually see lower rates, often 40–60% (Venugopal, 2024). 

Acute lymphoblastic leukemia (ALL)

Remission rates for ALL are very high, especially in children: about 90–95% reach complete remission after a first treatment. Adults are slightly lower, typically around 78–92% (Kantarjian, 2025). 

Chronic lymphocytic leukemia (CLL)

Remission rates for CLL depend on the treatment and patient factors. Newer targeted therapies help many people reach remission, though partial remission is more common. Complete remission rates vary widely, from about 8–88%, and MRD rates range from 47–81% (Munir, 2025). While remission can improve quality of life, CLL is rarely considered curable. 

Chronic myeloid leukemia (CML)

Rates for CML are high thanks to effective targeted therapies, especially tyrosine kinase inhibitors. Over 80% can expect long-term disease control, making CML a highly treatable chronic condition for most (Cortes, 2021).

What factors affect leukemia remission rates? 

Leukemia remission rates depend on many factors, related to you, your disease, and your treatment (Medeiros, 2019). 

Age at diagnosis 

Age strongly affects how well treatment works. Younger patients usually respond better and reach higher remission rates, since they tend to be healthier and handle intense therapies more easily. Older adults often see lower rates because of other health issues and weaker responses to treatment. 

Leukemia subtype 

Outcomes vary quite a bit from one type to another. ALL usually has higher remission rates, especially in children, and CML responds well to targeted therapies, so most people with it reach high remission rates. AML and CLL are more variable. 

Genetic mutations 

The genetics of your leukemia carry real weight. Some mutations, such as FLT3-ITD in AML and the Philadelphia chromosome in ALL, lower remission rates and raise the risk of relapse (Venugopal, 2024). More favorable mutations can improve how well treatment works. 

Genetic testing helps your doctor plan treatment and predict your outlook. 

Overall health 

Your general health going into treatment matters too. People in good health can usually handle more intensive treatments and are more likely to reach remission. Other health issues, organ problems, or low fitness can limit your options and lower remission rates. 

Treatment response 

How your leukemia answers the first round of treatment tells doctors a lot. A quick, full response makes lasting remission more likely. A slow or incomplete one can mean the leukemia is more resistant, calling for different treatments and raising the risk of relapse. 

MRD status 

MRD status offers a deeper read on your response. MRD-negative status after treatment means a much higher chance of staying in remission and a lower risk of relapse (Cloos, 2026); MRD-positive means a higher chance the disease returns. 

Either way, MRD testing helps your doctor plan your care and track your progress. 

Stem cell transplant eligibility 

Being eligible for a stem cell transplant can make a big difference. Younger, healthier people who get one often find deeper, longer-lasting remissions, or even a cure. If a transplant isn’t an option because of age or health, less intensive treatments may be needed, which can mean lower remission rates and a higher chance of relapse.

How is remission measured? 

Doctors use several methods to measure remission. 

Blood tests 

Blood tests are usually the first check, looking at whether your white blood cells, red blood cells, and platelets have returned to normal. Your doctor may also examine a blood smear for abnormal or immature leukemia cells. 

Together, these show how well treatment is working and whether you’re in remission. 

Bone marrow biopsies 

A bone marrow biopsy gives a closer look. A small sample is examined under a microscope to compare healthy cells with leukemia cells. A low or undetectable level signals remission, and the findings guide treatment choices and prognosis. 

MRD testing 

MRD testing is a sensitive way to find low levels of leukemia cells left after treatment. 

Techniques like flow cytometry and molecular assays such as quantitative real-time PCR (RT-qPCR), droplet digital PCR (ddPCR), and next-generation sequencing (NGS) can detect it even when standard tests show remission. 

MRD negativity is associated with deeper remission and a lower risk of relapse. 

Imaging and additional monitoring 

Imaging adds another view. Scans such as ultrasound, CT, or PET check your lymph nodes, spleen, and other organs for signs of disease. 

Along with routine checkups and symptom monitoring, they help your doctor track remission, especially if your leukemia affects organs beyond the bone marrow.

Can leukemia come back after remission? 

Leukemia can come back after remission. This is known as relapse. Even when standard tests detect no leukemia cells, a small number may remain and cause the disease to return months or years later. 

Understanding relapse 

A relapse means leukemia cells have reappeared in your blood or bone marrow after a period of remission. It often means the leukemia is more resistant and may need different or additional treatments to get back into remission. 

Factors linked to recurrence 

Certain factors can increase your risk of relapse: 

• Measurable residual disease after treatment 
• High-risk genetic mutations 
• Older age 
• Poor response to your first therapy 

Not reaching full remission, having certain types of leukemia, or being unable to have a stem cell transplant can also raise the risk of relapse. How much these factors affect relapse risk varies from person to person. 

Warning signs doctors monitor 

Doctors watch for signs that leukemia might return: 

• Unexplained tiredness 
• Frequent infections 
• Easy bruising or bleeding 
• Swollen lymph nodes 

Unusual blood counts or leukemia cells, plus changes on a bone marrow biopsy, can signal a possible relapse. 

Treatment options if leukemia returns 

If leukemia comes back, options may include more chemotherapy, targeted therapies, immunotherapy, a clinical trial, CAR T-cell therapy, or a stem cell transplant if you’re eligible. 

The best choice depends on your type of leukemia, past treatments, health, and genetics. The goal is to reach remission again or keep the disease under control—and your care team will help determine the best way to get you to that point.

Life after leukemia remission 

Life after remission involves ongoing follow-up and emotional adjustment. Many people find a new sense of normal, though regular monitoring and support remain essential for long-term health and peace of mind. 

Follow-up appointments

Even in remission, you’ll need regular checkups, including blood tests, physical exams, and monitoring for relapse or long-term effects of treatment. They help keep you healthy and catch problems early. 

Monitoring blood counts 

Tracking your blood counts is important after remission. Regular tests can spot early signs of relapse, flag complications, and let your doctor act quickly if needed. 

Emotional recovery 

Healing is emotional as well as physical. You may feel anxiety, relief, or worry about relapse.​ ​Support groups, counseling, and talking openly with others can help you cope. 

Managing fear of recurrence 

Fear of recurrence is common after remission. Talking openly with your healthcare team, using stress-reduction techniques, and keeping up healthy routines may help you feel more supported and more in control. Regular follow-up with your healthcare team can also help reassure you that your leukemia is still in remission and being closely monitored. 

Survivorship resources 

Survivorship resources, including counseling, support groups, patient education, and survivorship clinics, address your physical, emotional, and social needs. 

Many hospitals and ​​​​organizations—including Blood Cancer United—offer programs to help you manage long-term effects, monitor your health, and adjust to life after treatment.

Advances improving leukemia remission rates 

Several recent advances have improved remission rates for many people. Your care team will help you figure out whether traditional treatment or a newer therapy is most appropriate for your unique health needs and your specific leukemia. 

Targeted therapies 

Targeted therapies focus on the specific genetic mutations or proteins that drive cancer growth (Kantarjian, 2021). Drugs like tyrosine kinase inhibitors for CML and monoclonal antibodies for other types of cancer are more precise and cause fewer side effects, which raises remission rates. 

Immunotherapy 

Immunotherapy uses the body’s own immune system to target cancer cells. CAR T-cell therapy and immune checkpoint inhibitors have shown success (Kharfan-Dabaja, 2025), especially in relapsed or resistant cases. While everyone’s situation is different, these therapies can offer some people the hope of longer remission and better survival. 

Precision medicine 

Precision medicine tailors therapy to each patient’s genes and disease traits (Döhner, 2021). Using genetic testing and molecular profiling, doctors pick the drugs and strategies most likely to work, which raises remission rates and reduces side effects. 

Improved MRD testing 

Better MRD testing detects leftover cancer cells earlier and more sensitively after treatment (Berry, 2017). That lets doctors adjust therapy quickly, personalize plans, and spot relapse risk sooner, improving the odds of sustained remission. 

Stem cell transplant advances 

Stem cell transplants have advanced too, with more donor options, refined conditioning regimens, and better supportive care. 

Techniques like haploidentical transplants (using a half-matched donor such as a parent, child, or sibling) and improved graft-versus-host disease management have increased safety and eligibility (Nishiwaki, 2024). This gives more patients access to this potentially curative treatment and longer remissions.

FAQs 

What is the prognosis for leukemia in adults? 

It depends on the type of leukemia, your age, and the specific features of the cancer. In adults, acute leukemias generally have a worse prognosis than chronic ones. 

Is leukemia treatable in older adults? 

Yes, though remission rates are lower with age. Targeted therapies and immunotherapies have significantly improved the prognosis. 

What type of leukemia can you live with? 

Advances in the treatment of chronic leukemias, such as CLL and CML, often allow patients to live for many years. 

Does remission mean leukemia is cured? 

Not on its own. Remission means symptoms are gone and blood counts are normal. However, a small number of cancer cells may remain and could cause a relapse, so ongoing monitoring and sometimes more treatment are needed. It’s a big milestone, but doctors usually wait years without relapse before calling leukemia cured. 

What are the chances leukemia comes back after remission? 

It depends on the type of leukemia, your age, genetic markers, and treatment response, with acute leukemias generally carrying a higher risk. Some people stay in remission for years; others see a recurrence within months. Regular monitoring and blood tests are key to catching relapse early.

How Blood Cancer United supports people living with leukemia 

Wherever you are with remission, relapse, or life after treatment, you do not have to face it alone. 

Blood Cancer United is the largest global nonprofit focused on blood cancer patient support, research, and advocacy. Our mission is to cure blood cancer and improve the quality of life of all patients and their families. 

To achieve it, we unite a community of people: patients and their families, volunteers, healthcare providers, scientists, staff, partners, fundraisers, and philanthropists, who believe all blood cancer patients deserve longer, better lives. 

Since our founding in 1949, we have consistently evolved to better serve people affected by all 100-plus types of blood cancers, including leukemia, lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms. ​​​​​

We offer free resources and personalized support for anyone affected by any type of blood cancer. We’ve invested more than $2 billion in research, which continues to increase survival rates. We also advocate nationally and locally for more accessible and affordable healthcare for all patients. 

If you’re interested in supporting our mission, please consider donating today.

References 

1. Litzow, Mark R. 2025. “The Origins of the Definition of Complete Remission in Acute Myeloid Leukemia.” Haematologica 110 (2): 268–69. https://doi.org/10.3324/haematol.2024.286629. 
2. Venugopal, Sangeetha, and Mikkael A. Sekeres. 2024. “Contemporary Management of Acute Myeloid Leukemia.” JAMA Oncology 10 (10): 1417. https://doi.org/10.1001/jamaoncol.2024.2662. 
3. DiNardo, Courtney D, Harry P Erba, Sylvie D Freeman, and Andrew H Wei. 2023. “Acute Myeloid Leukaemia.” The Lancet 401 (10393): 2073–86. https://doi.org/10.1016/s0140-6736(23)00108-3. 
4. Kantarjian, Hagop, Ibrahim Aldoss, and Elias Jabbour. 2025. “Management of Adult Acute Lymphoblastic Leukemia.” JAMA Oncology 11 (7): 771. https://doi.org/10.1001/jamaoncol.2025.0613. 
5. Munir, Talha, Sean Girvan, David A. Cairns, Adrian Bloor, David Allsup, Abraham M. Varghese, Satyen Gohil, et al. 2025. “Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia.” New England Journal of Medicine 393 (12): 1177–90. https://doi.org/10.1056/nejmoa2504341. 
6. Alrawashdh, Neda, Joan Sweasy, Brian Erstad, Ali McBride, Daniel O. Persky, Ivo Abraham. 2021. “Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017).” Annals of Hematology 100: 2501-2512. https://link.springer.com/article/10.1007/s00277-021-04600-1. 
7. Cortes, Jorge, Carolina Pavlovsky, and Susanne Saußele. 2021. “Chronic Myeloid Leukaemia.” The Lancet 398 (10314): 1914–26. https://doi.org/10.1016/s0140-6736(21)01204-6. 
8. Jabbour, Elias, and Hagop Kantarjian. 2025. “Chronic Myeloid Leukemia.” JAMA 333 (18): 1618. https://doi.org/10.1001/jama.2025.0220. 
9. Medeiros, Bruno C., Steven M. Chan, Naval G. Daver, Brian A. Jonas, and Daniel A. Pollyea. 2019. “Optimizing Survival Outcomes With Post-remission Therapy in Acute Myeloid Leukemia.” American Journal of Hematology 94 (7): 803–11. https://doi.org/10.1002/ajh.25484. 
10. Cloos, Jacqueline, Peter J. M. Valk, Christian Thiede, Konstanze Döhner, Gail J. Roboz, Brent L. Wood, Roland B. Walter, et al. 2026. “2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document From the ELN-DAVID MRD Working Party.” Blood 147 (11): 1147–67. https://doi.org/10.1182/blood.2025031480. 
11. Kantarjian, Hagop M., Tapan M. Kadia, Courtney D. DiNardo, Mary Alma Welch, and Farhad Ravandi. 2021. “Acute Myeloid Leukemia: Treatment and Research Outlook for 2021 and the MD Anderson Approach.” Cancer 127 (8): 1186–1207. https://doi.org/10.1002/cncr.33477. 
12. Kharfan-Dabaja, Mohamed A., Ambuj Kumar, Javier Pinilla-Ibarz, Jennifer R. Brown, Mazyar Shadman, Farrukh T. Awan, Saad S. Kenderian, et al. 2025. “Clinical Practice Recommendations on the Role of Allogeneic Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Patients With Chronic Lymphocytic Leukemia on Behalf of the American Society for Transplantation and Cellular Therapy.” Transplantation and Cellular Therapy 31 (8): 494–504. https://doi.org/10.1016/j.jtct.2025.06.002. 
13. Döhner, Hartmut, Andrew H. Wei, and Bob Löwenberg. 2021. “Towards Precision Medicine for AML.” Nature Reviews Clinical Oncology 18 (9): 577–90. https://doi.org/10.1038/s41571-021-00509-w. 
14. Berry, Donald A., Shouhao Zhou, Howard Higley, Lata Mukundan, Shuangshuang Fu, Gregory H. Reaman, Brent L. Wood, Gary J. Kelloff, J. Milburn Jessup, and Jerald P. Radich. 2017. “Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia.” JAMA Oncology 3 (7): e170580. https://doi.org/10.1001/jamaoncol.2017.0580. 
15. Nishiwaki, Satoshi, Isamu Sugiura, Shin Fujisawa, Yoshihiro Hatta, Yoshiko Atsuta, Noriko Doki, Shingo Kurahashi, et al. 2024. “Utility of Allogeneic Stem Cell Transplantation for Adult Ph+ALL With Complete Molecular Remission.” American Journal of Hematology 99 (5): 806–15. https://doi.org/10.1002/ajh.27237.